Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
54 Results for "
Tumor-associated macrophages
" in MedChemExpress (MCE) Product Catalog:
Products (54)
54 Results for "Tumor-associated macrophages" in MCE Product Catalog:
278
278 Publications Verification
Synonyms: PS-341; LDP-341; NSC 681239
Research Areas:
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
13
13 Cited Publications
JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages .
2
2 Cited Publications
Synonyms: (Z)-Leukadherin-1 choline
Target:
Research Areas:
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses .
1
Target:
Research Areas:
Cat. No.: HY-W020780
CAS No.: 724722-89-8
Synonyms: mPEG5000-Maleimide
Cat. No.: HY-P6292A
Target:
Research Areas:
Cat. No.: HY-P99245
CAS No.: 1448221-67-7
Synonyms: RG 7155; RO 5509554
Cat. No.: HY-P99950
CAS No.: 2484949-51-9
Synonyms: ALX148
Cat. No.: HY-P991316
Synonyms: DX-2400; DX-2410
Target:
Research Areas:
Cat. No.: HY-10227R
CAS No.: 179324-69-7
Synonyms: PS-341 (Standard); LDP-341 (Standard); NSC 681239 (Standard)
Research Areas:
Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
Cat. No.: HY-P990651
Target:
Research Areas:
Cat. No.: HY-P10449
CAS No.: 3098205-40-1
Target:
Research Areas:
Cat. No.: HY-159838
CAS No.: 2222689-47-4
Synonyms: EI‐1071
Research Areas:
Enrupatinib (EI‐1071) is a potent, orally active, CNS-penetrant and selective CSF1R inhibitor. Enrupatinib inhibits macrophage proliferation and osteoclast differentiation in vitro. Enrupatinib preserves microglia distal to Aβ plaques. Enrupatinib mitigates Alzheimer's disease (AD)-related pathologies by reducing neuroinflammation, preserving neuronal integrity, lowering disease-associated microglia gene expression, and enhancing cognitive function in 5xFAD and J20 mouse models. Enrupatinib reduces tumor-associated macrophage infiltration and enhances antitumor activity of anti-PD-1 antibody in murine colorectal cancer and breast cancer models. Enrupatinib can be used for the research of AD, colorectal cancer, and breast cancer .
Cat. No.: HY-P11108
CAS No.: 1895883-60-9
Target:
Research Areas:
Cat. No.: HY-P99746
CAS No.: 2058047-65-5
Synonyms: 3C23K; GM102
Target:
Research Areas:
Cat. No.: HY-10227S
Purity: ≥98.0%
Synonyms: PS-341-d8; LDP-341-d8; NSC 681239-d8
Cat. No.: HY-155052
CAS No.: 2642327-52-2
Target:
Research Areas:
PAD4-IN-2 is a highly tumor-targeted and irreversible PAD4 inhibitor with an IC50 of 1.94 μM. It selectively recognizes sialic acid on tumor surfaces and accumulates in tumor tissues, with distribution in the cytoplasm of tumor cells and nuclei of neutrophils. PAD4-IN-2 inhibits the PAD4-H3cit-NETs (Neutrophil Extracellular Traps) pathway, reduces senescent tumor-associated neutrophils, and promotes M1 macrophage polarization. The compound exhibits potent anti-tumor and anti-metastatic activities and is suitable for breast cancer research .
Cat. No.: HY-P990650
Target:
Research Areas:
Cat. No.: HY-P10894
CAS No.: 2283322-63-2
Target:
Research Areas:
Cat. No.: HY-163642
CAS No.: 2379727-88-3
TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
